Scholar Rock Holding Corporation Common Stock (SRRK)
Scholar Rock Holding Corporation (SRRK) is a biopharmaceutical company focused on discovering and developing medicines that target growth factors involved in serious medical conditions. Its approach emphasizes precision medicine aimed at diseases such as fibrosis and cancer, utilizing its proprietary drug discovery platform to develop first-in-class therapeutics.
Company News
Scholar Rock's stock dropped over 13% after the FDA designated a Catalent Indiana manufacturing facility as Official Action Indicated (OAI), following a previous FDA rejection of its spinal muscular atrophy drug application.
Multiple stocks saw significant gains on Friday, with Crinetics Pharmaceuticals leading the pack after FDA approval, while other companies like BlackBerry, Perpetua Resources, and Scholar Rock also experienced notable stock price increases.
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.